AP NEWS

Health Canada Issues Medical Device License to ivWatch

August 2, 2018

ivWatch was issued a medical device license (MDL) by Health Canada permitting the company to sell the ivWatch Model 400 to Canadian health care organizations. (Photo: Business Wire)

HAMPTON, Va.--(BUSINESS WIRE)--Aug 2, 2018--ivWatch, the only provider of continuous monitoring devices for the early detection of intravenous (IV) infiltrations and extravasations, was recently issued a medical device license (MDL) by Health Canada permitting the company to sell the ivWatch Model 400 to Canadian health care organizations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180802005092/en/

ivWatch was issued a medical device license (MDL) by Health Canada permitting the company to sell the ivWatch Model 400 to Canadian health care organizations. (Photo: Business Wire)

“This is yet another milestone allowing more medical care providers and patients access to a first-of-its-kind technology to minimize harm from peripheral IV infiltration/extravasation events (PIVIEs),” said Scott Hensley, vice president of sales and business development at ivWatch. “Canada is one of the most progressive health care markets in the world and acknowledge PIVIEs as serious safety events. Clinicians understand the need for surveillance monitoring to improve patient safety.”

Every infiltration is a medication dosing and delivery error that can impact the patient through prolonged hospital stays, temporary harm or permanent injuries. Beyond the patient safety impact, any of these adverse events may result in increased expenses, significant legal risk and reputation damage for health care providers and facilities.

“We’re excited to work with health systems and pediatric hospitals who have quality improvement measures in place and stand ready to implement technology capable of drastically reducing the time to detect a PIVIE beyond what is currently possible by visual and tactile assessment,” said Hensley.

The MDL is the final step for Canadian market entry and was preceded by the company’s achievement of ISO 13485 Certification, the global standard for medical device quality management systems (QMS) developed by the International Organization for Standardization (ISO ® ).

To learn more about ivWatch and the Model 400, visit  www.ivWatch.com.

About ivWatch:

ivWatch, LLC  is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter  @ivWatch  or Facebook  @ivWatchLLChttps://www.ivwatch.com/

View source version on businesswire.com:https://www.businesswire.com/news/home/20180802005092/en/

CONTACT: ivWatch, LLC

Amara Betoney, 757-224-2606

Office 855-489-2824 x7007

Mobile 757-660-4949

amara.betoney@ivwatch.com

KEYWORD: UNITED STATES NORTH AMERICA CANADA VIRGINIA

INDUSTRY KEYWORD: SURGERY TECHNOLOGY HARDWARE PRACTICE MANAGEMENT HEALTH BIOTECHNOLOGY HOSPITALS MEDICAL DEVICES MANUFACTURING OTHER MANUFACTURING MEDICAL SUPPLIES NURSING MANAGED CARE

SOURCE: ivWatch, LLC

Copyright Business Wire 2018.

PUB: 08/02/2018 09:00 AM/DISC: 08/02/2018 09:00 AM

http://www.businesswire.com/news/home/20180802005092/en

AP RADIO
Update hourly